A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
Study identifier:D8750C00008
ClinicalTrials.gov identifier:NCT07220954
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living with Overweight or Obesity
Medical condition
Healthy Participants
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2 (high concentration), AZD6234 Formulation 3
Sex
All
Actual Enrollment
19
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 11 Nov 2025
Primary Completion Date: 16 Sept 2026
Study Completion Date: 16 Sept 2026
Study design
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment
Verification:
Verified 01 Oct 2026 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Quotient Sciences Limited
Inclusion and exclusion criteria
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Sequence ABCD Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment A in Period 1, Treatment B in Period 2, Treatment C in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) | Drug: AZD6234 Formulation 1 AZD6234 Formulation 1 will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 2 (low concentration) AZD6234 Formulation 2 (low concentration) will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 2 (high concentration) AZD6234 Formulation 2 (high concentration) will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 3 AZD6234 Formulation 3 will be administered as a single SC injection Other Name: AZD6234 |
| Experimental: Sequence BCAD Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment B in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) | Drug: AZD6234 Formulation 1 AZD6234 Formulation 1 will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 2 (low concentration) AZD6234 Formulation 2 (low concentration) will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 2 (high concentration) AZD6234 Formulation 2 (high concentration) will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 3 AZD6234 Formulation 3 will be administered as a single SC injection Other Name: AZD6234 |
| Experimental: Sequence CABD Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment C in Period 1, Treatment A in Period 2, Treatment B in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) | Drug: AZD6234 Formulation 1 AZD6234 Formulation 1 will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 2 (low concentration) AZD6234 Formulation 2 (low concentration) will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 2 (high concentration) AZD6234 Formulation 2 (high concentration) will be administered as a single SC injection Other Name: AZD6234 Drug: AZD6234 Formulation 3 AZD6234 Formulation 3 will be administered as a single SC injection Other Name: AZD6234 |
